You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 10, 2025

Claims for Patent: 9,687,474

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,687,474

Title:	Patch
Abstract:	In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, isopropyl palmitate, and an adhesive base agent.
Inventor(s):	Suzuki; Masayuki (Tsukuba, JP), Okutsu; Hiroaki (Tsukuba, JP), Yasukochi; Takashi (Tsukuba, JP), Takada; Yasunori (Tsukuba, JP)
Assignee:	HISAMITSU PHARMACEUTICAL CO., INC. (Tosu-shi, JP)
Application Number:	14/416,964
Patent Claims:	1. A patch, comprising: a support layer; and an adhesive agent layer formed on the support layer and comprising isopropyl palmitate, an adhesive base agent, sodium diacetate, and at least one of asenapine and a pharmaceutically acceptable salt thereof, wherein a mass ratio of the asenapine and/or pharmaceutically acceptable salt in terms of free asenapine to the isopropyl palmitate in the adhesive agent layer is in a range of 1:0.1 to 1:5. 2. The patch according to claim 1, wherein a mass ratio of the asenapine and/or pharmaceutically acceptable salt in terms of free asenapine to the isopropyl palmitate in the adhesive agent layer is in a range of 1:0.41 to 1:5. 3. The patch according to claim 1, wherein a mole ratio of the asenapine and/or pharmaceutically acceptable salt to the sodium diacetate in the adhesive agent layer is in a range of 1:0.5 to 1:4. 4. The patch according to claim 1, wherein the adhesive base agent is at least one selected from the group consisting of a (meth)acrylic ester (co)polymer, a rubber-based adhesive agent, a silicone polymer, and a polyurethane-based adhesive agent. 5. The patch according to claim 1, wherein when a content of the asenapine and/or pharmaceutically acceptable salt in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC.sub.2-120 for a period starting from the time when the patch is brought into contact with skin for 24 hours is 27,000 pghr/mL or more, and an AUC.sub.2-120 of an asenapine metabolite is 20% or less of the AUC.sub.2-120 of the free asenapine. 6. The patch according to claim 2, wherein a mole ratio of the asenapine and/or pharmaceutically acceptable salt to the sodium diacetate in the adhesive agent layer is in a range of 1:0.5 to 1:4. 7. The patch according to claim 2, wherein the adhesive base agent is at least one selected from the group consisting of a (meth)acrylic ester (co)polymer, a rubber-based adhesive agent, a silicone polymer, and a polyurethane-based adhesive agent. 8. The patch according to claim 2, wherein when a content of the asenapine and/or pharmaceutically acceptable salt in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC.sub.2-120 of the free asenapine for a period starting from the time when the patch is brought into contact with skin for 24 hours is 27,000 pghr/mL or more, and an AUC.sub.2-120 of an asenapine metabolite is 20% or less of the AUC.sub.2-120 of the free asenapine. 9. The patch according to claim 3, wherein the adhesive base agent is at least one selected from the group consisting of a (meth)acrylic ester (co)polymer, a rubber-based adhesive agent, a silicone polymer, and a polyurethane-based adhesive agent. 10. The patch according to claim 3, wherein when a content of the asenapine and/or pharmaceutically acceptable salt in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC.sub.2-120 of the free asenapine for a period starting from the time when the patch is brought into contact with skin for 24 hours is 27,000 pghr/mL or more, and an AUC.sub.2-120 of an asenapine metabolite is 20% or less of the AUC.sub.2-120 of the free asenapine. 11. The patch according to claim 4, wherein when a content of the asenapine and/or pharmaceutically acceptable salt in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC.sub.2-120 of the free asenapine for a period starting from the time when the patch is brought into contact with skin for 24 hours is 27,000 pghr/mL or more, and an AUC.sub.2-120 of an asenapine metabolite is 20% or less of the AUC.sub.2-120 of the free asenapine. 12. The patch according to claim 7, wherein when a content of the asenapine and/or pharmaceutically acceptable salt in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC.sub.2-120 of the free asenapine for a period starting from the time when the patch is brought into contact with skin for 24 hours is 27,000 pghr/mL or more, and an AUC.sub.2-120 of an asenapine metabolite is 20% or less of the AUC.sub.2-120 of the free asenapine. 13. The patch according to claim 6, wherein the adhesive base agent is at least one selected from the group consisting of a (meth)acrylic ester (co)polymer, a rubber-based adhesive agent, a silicone polymer, and a polyurethane-based adhesive agent. 14. The patch according to claim 6, wherein when a content of the asenapine and/or pharmaceutically acceptable salt in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC.sub.2-120 of the free asenapine for a period starting from the time when the patch is brought into contact with skin for 24 hours is 27,000 pghr/mL or more, and an AUC.sub.2-120 of an asenapine metabolite is 20% or less of the AUC.sub.2-120 of the free asenapine. 15. The patch according to claim 13, wherein when a content of the asenapine and/or pharmaceutically acceptable salt in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC.sub.2-120 of the free asenapine for a period starting from the time when the patch is brought into contact with skin for 24 hours is 27,000 pghr/mL or more, and an AUC.sub.2-120 of an asenapine metabolite is 20% or less of the AUC.sub.2-120 of the free asenapine. 16. The patch according to claim 9, wherein when a content of the asenapine and/or pharmaceutically acceptable salt in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC.sub.2-120 of the free asenapine for a period starting from the time when the patch is brought into contact with skin for 24 hours is 27,000 pghr/mL or more, and an AUC.sub.2-120 of an asenapine metabolite is 20% or less of the AUC.sub.2-120 of the free asenapine. 17. The patch according to claim 3, wherein a mass ratio of the asenapine and/or pharmaceutically acceptable salt in terms of free asenapine to the isopropyl palmitate in the adhesive agent layer is in a range of 1:0.5 to 1:5.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.